Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus PT from Analysts

Precigen, Inc. (NASDAQ:PGEN) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $7.00.

A number of analysts have recently commented on PGEN shares. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Precigen in a research note on Friday, November 15th. JMP Securities cut their target price on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 15th.

Institutional Investors Weigh In On Precigen

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Precigen by 0.3% in the first quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after acquiring an additional 19,875 shares during the period. Iridian Asset Management LLC CT raised its holdings in Precigen by 82.5% during the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after purchasing an additional 1,706,815 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares during the period. State Street Corp boosted its stake in shares of Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after purchasing an additional 29,253 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Precigen by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after purchasing an additional 127,467 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Price Performance

NASDAQ PGEN opened at $0.78 on Friday. Precigen has a twelve month low of $0.76 and a twelve month high of $1.93. The business’s fifty day moving average is $0.88 and its 200 day moving average is $1.19. The company has a market cap of $227.44 million, a price-to-earnings ratio of -1.41 and a beta of 1.71.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.